<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485821</url>
  </required_header>
  <id_info>
    <org_study_id>MS39825273</org_study_id>
    <nct_id>NCT02485821</nct_id>
  </id_info>
  <brief_title>Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol</brief_title>
  <official_title>Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of vaginal estradiol pretreatment before vaginal misoprostol on labor
      induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective double blind randomized clinical trial. Conducted at Ain Shams University
      Maternity Hospital. Patients fulfilling inclusion and exclusion criteria will be divided into
      two groups. Group (A):

      100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol
      manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet
      (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated
      every 6hours up to five doses.

      Group (B):

      100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated
      every 6 hours up to five doses.

      Primary Outcome

        -  Measure the time to cervical ripening. Secondary Outcome

        -  Measure the time to active labor.

        -  Number of misoprostol doses.

        -  Induction delivery time.

        -  Time to achieve vaginal delivery.

        -  Fetal outcome (Apgar score).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to cervical ripening.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to active labor</measure>
    <time_frame>30 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of misoprostol doses</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction delivery time</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Failed Induction of Labor</condition>
  <arm_group>
    <arm_group_label>Estradiol + Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Misoprostol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <arm_group_label>Estradiol + Misoprostol</arm_group_label>
    <other_name>Ethinyl Estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>Estradiol + Misoprostol</arm_group_label>
    <arm_group_label>Placebo + Misoprostol</arm_group_label>
    <other_name>Vagiprost</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Maternal age ≥ 18 years old.

          -  Gestational age ≥ 37 wks to 41 wks.

          -  BMI between 20 kg/m2 and 35kg/m2.

          -  Vertex presentation.

          -  Singleton pregnancy.

        Exclusion criteria:

          -  Multiple pregnancy.

          -  Non vertex presentation.

          -  Absolute or relative contraindication to vaginal delivery e.g. (Placenta previa,
             fibroid uterus, uterine anomalies, previous uterine surgery).

          -  PROM.

          -  IUFD.

          -  Fetal distress.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama El-Kady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AbdEl-Latif El-Kholy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>February 14, 2016</last_update_submitted>
  <last_update_submitted_qc>February 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Mohamed S. Sweed lecturer of Obstetrics &amp; Gynecology AinShams University.</investigator_title>
  </responsible_party>
  <keyword>Estradiol</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Induction of labor</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Bishop score</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

